Below are some examples of current studies that are taking place in the Trust. We always need people to take part in research. If you are interested in taking part in research, please speak to your care co-ordinator or clinician. You can download a printable version of our studies here

Studies for people who experience psychosis

The Atlas Trial: A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis.
Chief Investigator: Robert Howard
Local Investigator: Pranathi Ramachandra
The ATLAS trial aims to test the use of antipsychotic medication in people over 60 years of age who are currently going through their first episode of psychotic illness. The onset of psychosis in people over 60 is relatively rare and little is known about what might constitute an effective treatment for this group of people. The ATLAS trial aims to address this by testing whether antipsychotic medication used in younger people is also effective in this age group.
Study contact: katherine.cummergen@cpft.nhs.uk or call 01223 746174

PPIP3: Prevalence of neuronal cell surface antibodies in patients with psychotic illness - extension study. Determining the clinical relevance of pathogenic antibodies in psychosis
Chief Investigator: Belinda Lennox
Local Investigator: Jesus Perez
The PPiP3 study is a continuation of the PPiP study, which is looking at the role of antibodies as a cause of psychosis. A small but significant percentage of the total number of first episodes of psychosis may be caused by an immune response and may be treatable by immunotherapy. Identifying people for whom this is the case means having the ability to provide an effective treatment leading to a better than usual recovery. Participants with a first episode of psychosis who consent to taking part in this study will have a blood sample taken for analysis to determine whether there is an immunological cause for their illness. Participants will be paid £10.
Study contact: katherine.cummergen@cpft.nhs.uk or call 01223 746174 (Cambridge) and andy.foster@cpft.nhs.uk or call 07956 463208 (Peterborough)

An online randomised controlled trial to evaluate the clinical and cost effectiveness of a peer supported self-management intervention for relatives of people with psychosis or bipolar disorder: Relatives Education and Coping Toolkit (REACT)
Chief Investigator: Fiona Lobban
Local Investigator: Heather Robinson
The REACT intervention is a peer facilitated online intervention for relatives of people with psychosis or bipolar disorder. The REACT toolkit contains lots of information to help relatives, ideas of strategies to manage common problems, and storied from other relatives about their experiences. Through the site participants can contact a REACT Supporter who is a trained relative who can provide additional support relevant to participants' personal needs. There is also an online forum (REACT Group).The aim of the trial is to assess how well the toolkit works in terms of reducing distress and improving relatives' wellbeing. In order to take part in the study, you must have a relative who has psychosis or bipolar disorder, be looking for help and support, and have access to the Internet. If you take part, you will be randomly assigned to one of two groups: A group which has access to the toolkit and a group which will receive treatment as usual.
Study contact: katherine.cummergen@cpft.nhs.uk or call 07904 640082 (Cambridge) and andy.foster@cpft.nhs.uk or call 07956 463208 (Peterborough).


Studies for people who experience schizophrenia

DPIM – schizophrenia: DNA Polymorphisms in mental illness
Chief Investigator: Andrew McQuilland
Local Investigator: Zahoor Syed
The DPIM project is a long-running study aiming to identify genetic changes that may make people more likely to develop schizophrenia, bipolar disorder or alcohol dependence. Identifying genetic markers may help with the development of future treatments. Taking part in the study involves having a blood sample taken and completing a number of questionnaires.
Study contact: Cambridge katherine.cummergen@cpft.nhs.uk or call 01223 746174 and alison.stribling@cpft.nhs.uk or call 01223 746029 Peterborough andy.foster@cpft.nhs.uk or call 07956 463208

Studies for people experiencing Obsessive Compulsive Disorder (OCD)

Avoidance in OCD: An investigation of the neural correlates of active avoidance in obsessive compulsive disorder
Chief Investigator: Trevor Robbins
Local Investigator: Emilio Fernandez-Egea
This project is run by a team based at the University of Cambridge and it is looking for people aged between 18 and 70 years old to participate in a study investigating brain activity during learning in individuals with OCD. The study involves completing some questionnaires and computer tasks and participants may be asked to perform some tasks while lying in an MRI scanner (this is optional). The study requires those who take part to come to Cambridge and each testing session will take about three hours. Participants will be reimbursed £50 (if the testing involves scanning) or £25 (for a behavioural testing session) for participation plus all travel expenses.
Study contact: alison.stribling@cpft.nhs.uk or call 01223 746029

The Cognitive Profile of Early-Onset Obsessive-Compulsive Disorder
Chief Investigator: Barbara Sahakian
This study, run by a team at the University of Cambridge, is looking for people with OCD who are 12 to 19 years old (inclusive). The study is about how young people with OCD learn, make decisions and control their actions. Those who participate must have a primary diagnosis of OCD and no additional psychiatric disorders, be a fluent or native English speaker, have normal or corrected-to-normal vision and have no current or previous alcohol or drug dependence. The study, which takes about four hours, involves a few tasks on a touch-screen computer, questionnaires and a short interview with a Psychiatrist. Participants can either travel to Cambridge or the study team can travel to local towns. Participants will be paid £40 and any travel expenses will also be reimbursed.
Study contact: alison.stribling@cpft.nhs.uk or call 01223 746029

Studies for people who have ADHD

Dopaminergic modulation of cognition in adults with attention-deficit hyperactivity disorder (ADHD)
Chief Investigator: Sam Chamberlain
Local Investigator: Sam Chamberlain
This study is exploring whether a medication, acting on the brain's dopamine system, can improve cognitive functions (such as memory and attention) in adults with ADHD. We are recruiting men with ADHD aged 18-50 years. The study involves two visits to Addenbrooke's Hospital, taking a pill each time (containing a dopamine medication, or placebo, in a random order), and doing some computer puzzles. Participants are given £75 for each visit. 
Study contact: sam.chamberlain@cpft.nhs.uk or ulrich.muller@cpft.nhs.uk
or telephone  01223 884098

Studies into genetics and mental illness

Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies
Chief Investigator: Munir Pirmohamed
Local Investigator: Emilio Fernandez-Egea
This project is looking for participants who have experienced a serious adverse reaction to Clozapine, with the aim of identifying genetic factors which may make people likely to react badly to this drug. Anyone who has ever experienced a serious reaction to Clozapine can take part. The project is also recruiting a small munmber of participants who have taken clozapine for at least a year, without experiencing an adverse reaction. Participants will be asked to provide a blood or saliva sample and to answer some questions about their medical wellbeing.
Study contact: alison.stribling@cpft.nhs.uk or call 01223 746029

Studies for people experiencing substance misuse

DPIM – alcohol: DNA Polymorphisms in mental illness
See above.

Studies for people experiencing depression

BIOmarkers in DEPression (BIODEP): Peripheral immunomarker validation in treatment-resistant depression
Chief Investigator: Ed Bullmore
Local Investigator: Ed Bullmore
This study aims to use biomarkers to identify the subset of depressed patients who are most likely to respond better to an anti-inflammatory drug than to conventional anti-depressants. There is evidence that inflammation is often associated with, and can cause, depression. But there is less evidence to show whether anti-inflammatory drugs have a meaningful anti-depressant effect.
Participants in this study will be asked to take part in a fasting blood sample, clinical interview and a series of psychiatric questionnaires, for which they will be paid £100. Participants may have the option of attending for a second, voluntary visit which will involve a further fasting blood sample, MRI and questionnaires, for which the payment will be £125, with the added options of having a PET scan (in London) and a lumbar puncture for which additional payments will be provided.
Study contact: clare.knight@cpft.nhs.uk or call 01733 316701 and amber.dickinson@cpft.nhs.uk or call 01223 7460877

Studies for people experiencing dissociative seizures

CODES: COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures: A multicentre randomised controlled trial
Chief Investigator: Laura Goldstein
Local investigator: Cathy Walsh
The CODES study is trying to establish whether Cognitive Behavioural Therapy (CBT) can improve outcomes and quality of life for people who have seizures but do not have epilepsy (Dissociative Non-Epileptic Seizures). The aim is to find out whether CBT can reduce the frequency of seizures as well as improving overall quality of life and reducing the costs of seizures to both the patient and the NHS in terms of treatment and disability. Participants will already have taken part in the initial phase of the study, which is recruiting people from Neurology clinics. Participants are randomly assigned to one of two groups: One group will receive standard carer, while the other will receive CBT & standard care. Those taking part will complete a series of tests and questionnaires both before and after the treatment. Some travel costs can be reimbursed for taking part in this study.
Study contact: alison.stribling@cpft.nhs.uk or call 01223 746029

Studies for people experiencing bipolar disorder

DPIM – alcoholism: DNA Polymorphisms in mental illness
Chief Investigator: Andrew McQuillan
Local Investigator: Zahoor Syed
The DPIM project is a long-running study aiming to recruit tens of thousands of people in order to identify genetic changes that may make people more likely to develop schizophrenia, bipolar disorder or alcohol dependence. Identifying genetic markers may help with the development of future treatments. Taking part in the study involves having a blood sample taken and completing a number of questionnaires. Visits can take place either in clinics or at the participants’ home. Participants are not paid to take part in this study.
Study contact: Cambridge katherine.cummergen@cpft.nhs.uk or call 01223 746174 and alison.stribling@cpft.nhs.uk or call 01223 746029. Peterborough andy.foster@cpft.nhs.uk or call 07956 463208

Studies for people experiencing perinatal mental illness

ESMI - The effectiveness of perinatal mental health services
Chief Investigator: Louise Howard 
The ESMI project aims to look for evidence of the effectiveness and cost-effectiveness of perinatal mental health services in the NHS. The project consists of multiple work packages:
- A package aimed at identifying depression and looking at the effectiveness of the tools currently in use to do this, then inviting women identified as having depression to take part in a trial comparing modified guided self-help with treatment as usual;
- A qualitative study capturing the experiences of women who have used perinatal mental health care. This study also aims to collate the experiences of partners, clinicians and GP commissioners;
- A package investigating the effectiveness of services for women with severe perinatal mental illness.
Study contact: katherine.cummergen@cpft.nhs.uk or call 01223 746174

Studies for people experiencing post-stroke aphasia

No studies recruiting presently. 

Studies for young people who have experienced mental illness

Neuroscience Clinical Adolescent and Adult Psychiatry Study (NCAAPS)
Chief Investigator: Ian Gooyer
Local Investigator:Ed Bullmore and Peter Jones
This study aims to learn how people’s brains develop and change over their teens and twenties, and particularly to understand more about brain development in young people who may have experienced mental illness. The study team would like to work with people aged between 14 and 35 who have had treatment or are currently receiving treatment for mental health problems. Taking part in the study will involve psychological interviews, computer tasks and questionnaires. An MRI scan will also be taken. Participants may be followed up for up to five years.
Study contact: alison.stribling@cpft.nhs.uk or call 07940 555116

Studies for people interested in mental ill health and physical health improvement

Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR Plus): a randomised evaluation of a bespoke smoking cessation service

Chief Investigator: Simon Gilbody
Local Investigator: Julie Ferris 
Smoking and smoking heavily is common in people who have experienced severe mental illness. The health consequences of smoking are well known, but people who have experienced severe mental illness are among the least likely to receive support to stop smoking. 
The SCIMITAR-Plus project aims to test the effectiveness of a smoking cessation method tailored to people who have severe mental illness with a view to improving physical health and reducing early deaths from smoking-related illnesses. Participants in the study will be allocated to one of two groups: one group will receive the specialist smoking cessation support, the other will receive treatment as usual, i.e. standard support for smoking cessation without the additional tailored elements.
Study contact: Alison.Stribling@cpft.nhs.uk or call 07940 555116

Studies in follow-up

BeneMin study
This study is looking at the benefits of a common antibiotic (Minocycline) on the negative symptoms of schizophrenia, such as apathy and social withdrawal, which can have a profound effect on quality of life. The study aims to find out whether Minocycline helps mitigate these symptoms and if so, how this occurs. Participants recruited in the Trust will be followed up for 15 months.

CIRCLE
The CIRCLE study is a randomised controlled trial looking at the effectiveness of an intervention aimed at reducing the cannabis use of people suffering from early psychosis. The study aims to compare the effectiveness of psychoeducation alone with the effectiveness of psychoeducation with the addition of a voucher system. Participants in the study will be followed up for a maximum of 18 months.

Studies for people experiencing Alzheimer’s Disease

ELAD study
Chief Investigator: Paul Edison
Local Investigator: Ben Underwood
The ELAD study is a trial of a medicine (liraglutide) currently used to treat diabetes to see if it has a positive effect on people with early stage Alzheimer’s disease. Participants will be allocated one of two groups: half will receive the medicine, the other half will receive a dummy drug (placebo). The medication is taken in the form of a daily injection. The study lasts for 52 weeks. All potential participants will be screened to see whether they are suitable for the study - this screening will involve collection of blood and urine samples as well as scans. Throughout the study, participants will be scanned again, will complete questionnaires and will be asked to undergo a lumbar puncture. It will be possible to take part in the study without undergoing the lumbar puncture. The study involves travel to London on several occasions. All travel expenses will be paid.
Study contact: Naomi.young1@nhs.net or call 01223 218659

Minocycline in Alzheimer’s Disease Efficacy (MADE) study
Chief Investigator: Robert Howard
Local Investigator: John O’Brien
The MADE trial aims to test whether an antibiotic drug called Minocycline can be used to slow down the progression of early stage Alzheimer’s disease. Participants will be randomly allocated to one of three groups: one taking a higher dose of Minocycline, one taking a lower dose of Minocycline and one taking a placebo (sugar pill). Before taking part, participants will have a medical check to ensure they are suitable for the study. Participants will be visited at different time points during the study to assess their continued wellbeing and progress. Participants will complete memory tests at different time points during the study. All visits for the study can take place at the participant’s home.
Study contact: rowan.simpson@nhs.net or call 01223 218629

AD Genetics
Chief Investigator: Julie Williams
Local Investigator: Ben Underwood
Early onset dementia is defined as the situation where the onset of illness starts before the age of 65. There is still much more to understand about this illness. The AD genetics study is aiming to find out which specific genes contribute to people developing Alzheimer’s Disease, with a view to improving future treatments. Within the Trust, the focus is specifically on early onset dementia. The purpose of recruiting people with early onset Alzheimer’s to AD Genetics is to gain a deeper understanding of factors that influence the progression of the illness. To take part in this study, participants will be visited in their own homes by two members of the study team They will have an interview and a memory test as well as giving a blood sample. Where possible the researcher will also interview a nominated family member or friend.
Study contact: Julie.philps@cpft.nhs.uk or call 01223 218681

Studies for people experiencing Lewy Body Dementia

Diamond-Lewy WP1
Chief Investigator: John O’Brien
Local Investigator: John O’Brien
The Diamond-Lewy project is an evaluation of services provided within Trusts specifically for the diagnosis and support of people with Lewy Body Dementia. The study involves looking at participants’ medical notes only - no face to face contact or medical procedures are involved.
Study contact: julie.philps@cpft.nhs.uk or call 01223 218681

Dementia Observational Studies

IDEAL
Chief Investigator: Linda Clare
Local Investigator: Neil Watson

The IDEAL project will study 1500 people experiencing difficulties with memory, thinking or behaviour that may have been described as dementia or an associated condition. It will also look at effects on family members or friends who provide support throughout the UK. 

The project draws together expertise from psychology, sociology, medicine, public health, economics, social policy, physiology and statistics.The aim is to help more people live well with dementia and to find out what makes this easier or more difficult for people to achieve. The findings from the study will help to identify what can be done by individuals, communities, health and social care practitioners, care providers and policy-makers to improve the likelihood of living well with dementia. Participants in the study will be asked to complete a set of questionnaires at the beginning of the study. These will be repeated every year for three years. In addition, some participants will be asked to take part in a more in depth interview.

Study contact: julie.philps@cpft.nhs.uk or call 01223 218681

PROMS (Evaluation of Memory Services)
Chief Investigator: Sarah Smith
Local Investigator: Kathrin Grosse
This study is looking at Memory Assessment Services from the patient and carer perspective. Carers and patients at Memory Assessment Clinics will be asked about their experiences of the service through a set of questionnaires. The questionnaires will be repeated 6 months later in a follow-up visit. Depending on how the service operates, participants can complete the questionnaires in clinic or they can be visited in their own homes.
Study contact: julie.philps@cpft.nhs.uk or call 01223 218681

BDR Donor Recruitment
Chief Investigator: Paul Francis
Local Investigator: Ben Underwood
This study aims to build a collection of donated brain tissue for analysis in order to study the causes and possible treatments for dementia. To take part in the study, participants must agree to donate their brain for research after death. Those with a diagnosis of Dementia will also be required to take part in annual memory testing to track the progress of their disease. The study is also looking at healthy people willing to donate their brains - this group will be tested less frequently. Study visits can take place in test centres, in the participant’s home or over the telephone in the case of healthy controls.
Study contact: lucy.canovas1@nhs.net or call 01223 218630

Other Dementia Studies

ATTILA
Chief Investigator: Robert Howard
Local Investigator: Andrew Bateman

The aim of the ATTILA study is to see whether certain electronic devices can enable people to live independently at home for longer. We will do this by comparing these newer devices (e.g. pill dispensers; fall detectors) with some widely-used standard devices (e.g. smoke detectors; walking frames). If you choose to take part, you will receive a package of care that includes either the newer devices and the standard devices; or the standard devices only. At the beginning of the study, we will visit you at home to ask some questions about your health and care. Following this we will arrange occasional home visits and phone calls to see how you are getting on. Taking part is entirely voluntary, and you may choose to withdraw at any time, without your care being affected. We may also invite your carer to take part in the study, as their views are also valuable to us.

Study contact: Ruth.Cloherty@cpft.nhs.uk or call 07983539499

Clinical Biomarkers for Dementia Research

Chief Investigator: John O’Brien
Local Investigator: John O’Brien
This project aims to streamline the process of memory assessment so that it is better aligned with research into dementia. Participants will be recruited from the group of patients who are already attending routine memory assessment clinics and at this point they will be asked for their consent to take part in the project. If consent is given, information additional to that already collected in clinic will be gathered so that as much useful data for research is obtained with a minimum of effort. People who consent to the research will have additional assessments carried out and some blood taken to look for clinical biomarkers for dementia.
Study Contact: michael.lewis@nhs.net

Cognitive Training in Mild Cognitive Impairment (iPAD)
Chief Investigator: Barbara Sahakian
Local Investigator: John O’Brien
The purpose of the study is to assess the impact of intensive use of handheld computer devices (iPads) to carry out computerised tasks which have been shown to have a positive effect on people experiencing mild cognitive impairment. Please note that this study is now closed to new participants.
Study contact: lucy.canovas1@nhs.net or call 01223 218630

NIMROD
Chief Investigator: John O’Brien
Local Investigator: John O’Brien
The NIMROD study is looking at the role of inflammation in the brain in the development of disorders like dementia of all kinds and also at depression. The association between brain inflammation and the above disorders is well known; what the NIMROD study aims to establish is whether there is a cause/effect connection, whether the presence of brain inflammation can predict whether or not a person will develop dementia or depression and whether new treatments are possible. Participation in the study can include some or all of the following: memory and reasoning tests, blood sampling, PET and MRI scanning and in some cases a lumbar puncture. The memory tests and blood sampling would be repeated every year for 3 years. Participants will receive travel expenses and can have all their travel arranged for them.
Study contact: gloria.calderon@nhs.net or call 01223 218 620

 

The page was last updated on 19 October 2017 by aient.

Cambridgeshire and Peterborough NHS Foundation Trust
Elizabeth House, Fulbourn Hospital
Cambridge, CB21 5EF

T 01223 219400 (open 8:30am to 5pm)
F 01480 398501

Twitter Logo Youtube Logo Facebook Logo Instagram Logo Wordpress Logo